Literature DB >> 8193377

Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient.

K R Oettel1, O H Wesly, M R Albertini, J A Hank, O Iliopolis, J A Sosman, K Voelkerding, S Q Wu, S S Clark, P M Sondel.   

Abstract

Immunocompetent cells in bone marrow allografts have been associated with a graft-versus-leukemia (GVL) effect. To further characterize effector mechanisms that may be involved in this GVL phenomenon, we have previously established an in vitro model to identify allogeneic T-cell clones that selectively mediate cytotoxicity against a patient's leukemic cells, but not against nonleukemic lymphocytes from the same patient. We have modified this in vitro model to test whether the Ph1 chromosome and the P210 fusion protein it controls have a detectable role in leukemia-specific recognition by allogeneic T-cell clones. In this report, T-cell lines reactive with allogeneic Ph1 chromosome-bearing (Ph1+) chronic myeloid leukemia (CML) cell lines were derived and selected to be minimally reactive with Ph1 negative (Ph1-) lymphoid lines from the same patient. However, after prolonged culture, these same T-cell lines also mediated significant destruction of the Ph1- target cells from the same patients. These T-cell lines specifically recognized cells from the allogeneic CML patient to which they were sensitized, and were not contaminated by an outgrowth of natural killer cells. Furthermore, subclones could be derived from these T-cell lines, and some of these subclones again showed selective killing of the allogeneic Ph1+ leukemia cell lines, and not of the Ph1- cell line from the same patient. Analyses of T-cell receptor (TCR) genes showed the alloreactive T-cell lines and the Ph1+ selective subclones derived from them to be of the same clonal origin. This suggests that the same T cells reacting with antigens expressed on the nonleukemic Ph1- targets can at times selectively and preferentially kill the allogeneic Ph1+ cells. As the same TCR that recognizes Ph1+ cells also can recognize the Ph1- targets, it appears that the Ph1+ chromosome does not play a detectable role in recognition by these allogeneic T-cell clones. This in vitro observation may provide a model for evaluating the relationship between GVL and graft-versus-host disease effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8193377

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.

Authors:  Suradej Hongeng; Sawang Petvises; Surapon Worapongpaiboon; Busaba Rerkamnuaychoke; Samart Pakakasama; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

2.  Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences.

Authors:  J Michalek; R H Collins; H P Durrani; P Vaclavkova; L E Ruff; D C Douek; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

Review 3.  Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.

Authors:  P Vandenberghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

4.  Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies.

Authors:  Yong-Qiu Wei; Xi-Nan Cen; Hui-Hui Liu; Yu-Hua Sun; Yong-Jin Shi; Wei Liu; Yu-Jun Dong; Han-Yun Ren
Journal:  Oncol Lett       Date:  2017-03-31       Impact factor: 2.967

5.  Myeloid Leukemias and Virally Induced Lymphomas in Miniature Inbred Swine: Development of a Large Animal Tumor Model.

Authors:  Raimon Duran-Struuck; Abraham J Matar; Christene A Huang
Journal:  Front Genet       Date:  2015-11-20       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.